FUSION PHARMACEUTICALS INC (FUSN)

Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...

Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order

/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as...

Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision...

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market

The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHRD, AA, FUSN, LABP

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, JBT

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024

/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, DOMA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)

INVESTIGATION ALERT: Halper Sadeh LLC Investigates LABP, FUSN, KNTE

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FUSN, DRQ, X

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023

FUSN stock results show that Fusion Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fusion Pharmaceuticals (NASDAQ:FUSN) just reported results for the fourth quart...

Kuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates

/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision...

FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –

Why Fusion Pharmaceuticals Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket

Shares of Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) rose sharply in today’s pre-market trading after the company agreed to be acquired by AstraZeneca for around $2 billion in cash.

Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover

The company is working on radiopharmaceuticals treatments for cancer.

Why Is Greenwave Tech Solutions (GWAV) Stock Down 53% Today?

Greenwave Tech Solutions stock is falling on Tuesday following an update on warrants for GWAV stock and other news this morning.

Why Is Ontrak (OTRK) Stock Up 105% Today?

Ontrak stock is on the rise Tuesday as OTRK investors are excited about an upcoming live fireside chat set for later today.

Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today?

Fusion Pharmaceuticals stock is rising higher on Tuesday as AstraZeneca agrees to acquire FUSN for $21 per share with a CVR of $3.